318 related articles for article (PubMed ID: 11795366)
1. Raloxifene: risks and benefits.
Barrett-Connor E
Ann N Y Acad Sci; 2001 Dec; 949():295-303. PubMed ID: 11795366
[TBL] [Abstract][Full Text] [Related]
2. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
3. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
6. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
Cohen FJ; Lu Y
Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
[TBL] [Abstract][Full Text] [Related]
7. Tolerability profile of SERMs.
Agnusdei D; Iori N
J Endocrinol Invest; 1999 Sep; 22(8):641-5. PubMed ID: 10532252
[No Abstract] [Full Text] [Related]
8. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene hydrochloride.
Snyder KR; Sparano N; Malinowski JM
Am J Health Syst Pharm; 2000 Sep; 57(18):1669-75; quiz 1676-8. PubMed ID: 11006795
[TBL] [Abstract][Full Text] [Related]
10. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
Ko SS; Jordan VC
Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
[TBL] [Abstract][Full Text] [Related]
11. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
12. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
13. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado Martín PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
14. Effect of SERMs on the uterus and menopausal symptoms.
Dören M
J Endocrinol Invest; 1999 Sep; 22(8):625-35. PubMed ID: 10532250
[No Abstract] [Full Text] [Related]
15. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
Chmel R; Rob L; Strnad P
Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene for older women: a review of the literature.
Hansdóttir H
Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
[TBL] [Abstract][Full Text] [Related]
18. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
19. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
Draper MW
Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
[TBL] [Abstract][Full Text] [Related]
20. Update on raloxifene to prevent endometrial-breast cancer.
Goldstein SR
Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
